Studies have shown that the BRAF V600E mutation can influence the tumour immune microenvironment by activating the MAPK pathway [56] and may inhibit ferroptosis [57], suggesting its potential role in immune evasion and treatment resistance. Here, BRAF is linked to neoplasm.